Key Drivers
- High cash cushion
- Heavy R&D burn
- Stretched solvency
AIAI Summary
IBRX has shifted from a binary R&D story into a revenue‑driven commercial company where ANKTIVA's prescription cadence and international rollouts (not just clinical data) will determine valuation — monitor monthly/quarterly ANKTIVA revenue, gross margin stability, and partner rollouts to judge sustainability. The key immediate risk is liquidity and leverage: watch cash burn, upcoming debt/refinancing timelines and sBLA milestones closely — sustained revenue acceleration with disciplined opex could materially de‑risk the stock, while missed cadence or need for dilutive financing would prompt sharp downside.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High cash cushion
- •Heavy R&D burn
- •Stretched solvency
IBRX combines strong cash/liquidity and very high gross margins with severe operating/R&D burn, negative equity and large long-term debt that, together with negative FCF, make current valuation look precarious.
Price Behavior
Key Price Behavior Insights:
- •Mild downtrend
- •Elevated volatility
- •Support holding
Over the last month the stock shows a mild downtrend with elevated volatility—price slipped from $8.70 to $8.47 (−2.6%), holding $7.8–$8.2 support but failing to sustain a spike to $11.55, implying event-driven upside potential amid higher short-term downside risk.
Sharp intraperiod spike to $11.55 on 2026-02-24 then pullback indicating event-driven volatility
Sentiment & News
Key News Insights:
- •Robust Anktiva sales
- •Global launches
- •Premium valuation
ImmunityBio's stock rally is driven by blockbuster Anktiva sales and accelerating global launches that materially lift revenues and clinical/operational momentum, but valuation and single‑product concentration remain key risks.
Continued commercial execution and upcoming regulatory/readouts should sustain upside, yet the high multiple increases vulnerability to any execution setbacks
Similar Companies in Healthcare
Other companies in the same sector with AI ratings